Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

Journal of Traditional Chinese Medicine, with the ISSN 0255-2922 and E-ISSN 1577-7014, is a distinguished publication dedicated to exploring the rich heritage and contemporary applications of Chinese medicinal practices. Published by JOURNAL TRADITIONAL CHINESE MED in China, this journal contributes significantly to the field of Complementary and Alternative Medicine, holding a respectable Q2 ranking in this category according to the 2023 metrics, and a Q3 ranking in miscellaneous medicine. With its coverage spanning from 1996 to 2024, the journal aims to advance scholarly research and foster an understanding of traditional Chinese healing methodologies, blending ancient wisdom with modern healthcare paradigms. While currently not classified as Open Access, it provides critical insights and detailed analyses that are invaluable for researchers, healthcare professionals, and students interested in the intersection of tradition and innovation in medical practices.

JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE, published by Mary Ann Liebert, Inc., stands at the forefront of research in the field of Complementary and Alternative Medicine. With an ISSN of 1075-5535 and an E-ISSN of 1557-7708, this journal has been a pivotal source of scholarly articles since its inception in 1995, although its coverage in Scopus was discontinued in 2021. Renowned for its rigorous peer-review process and high-quality contributions, the journal ranks 23rd out of 93 in the Medicine-Complementary and Alternative Medicine category, firmly positioning it in the 75th percentile. Aimed at researchers, professionals, and students, the journal provides accessible insights into the interdisciplinary studies of alternative therapies and holistic health practices. With evolving open access options, it continues to disseminate crucial knowledge that can shape future therapeutic developments and influence healthcare practices. Explore the impactful content that can support and expand your understanding of complementary medicine at JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE.

The Chinese Journal of Integrative Medicine, published by SPRINGER, serves as a pivotal platform for advancing the field of complementary and alternative medicine. Since its inception in 1995, this journal has been committed to disseminating high-quality research and innovative practices that integrate traditional Chinese medicine with modern medical science. With an impressive categorization in the 2023 metrics, ranking Q2 in Complementary and Alternative Medicine and Q3 in both Medicine (miscellaneous) and Pharmacology (medical), the journal highlights its recognition within the global academic landscape. Researchers and practitioners alike can benefit from its rigorous peer-reviewed articles, making significant contributions to the understanding and application of integrative health strategies. While it currently does not support open access, the journal remains a key resource for those dedicated to exploring the synergy between ancient practices and contemporary medical approaches, thus enhancing patient care and outcomes.

International Cancer Conference Journal, published by Springer International Publishing AG, serves as a pivotal platform for the dissemination of cutting-edge research in the field of oncology. With a commitment to advancing the understanding, prevention, and treatment of cancer, this journal offers a forum for the presentation of innovative studies, clinical trials, and comprehensive reviews that cater to the needs of researchers, healthcare professionals, and students alike. Although currently not open access, the journal is dedicated to fostering collaboration and knowledge sharing within the cancer research community. The ISSN for this journal is 2192-3183, ensuring its listing within prominent academic databases for enhanced visibility. Hailing from Switzerland, the journal aspires to impact the global dialogue on cancer through rigorous peer-reviewed articles and special conference proceedings, making it an essential resource for those dedicated to the fight against cancer.

Recent Patents on Anti-Cancer Drug Discovery, published by Bentham Science Publishers Ltd, is an esteemed peer-reviewed journal specializing in the innovative intersection of pharmaceutical science and oncology. With an ISSN of 1574-8928 and an E-ISSN of 2212-3970, this journal aims to provide a comprehensive platform for the dissemination of recent developments in anti-cancer drug discovery, addressing critical issues and breakthroughs that influence cancer research and treatment. The journal spans from 2006 to 2024 and is indexed in several prestigious databases, showcasing its relevance with a Q3 ranking in key categories such as Cancer Research and Drug Discovery as of 2023. Its status of being open access reflects a commitment to making valuable scientific findings widely available, promoting collaboration and advancement in the field. With a dedicated focus on advancing knowledge in cancer therapeutics, the journal serves as a vital resource for researchers, healthcare professionals, and students aiming to contribute to the fight against cancer.

Precision Medical Sciences is a pioneering open-access journal, launched in 2020 and published by the esteemed WILEY, dedicated to disseminating cutting-edge research and advancements in the field of precision medicine. With the ISSN 2642-2514, this journal serves as a critical platform for researchers, healthcare professionals, and students to explore innovative approaches that personalize medical treatment, optimize patient outcomes, and advance the understanding of patient variability in response to therapies. The adoption of open-access policies ensures that groundbreaking findings are readily available to the global scientific community, fostering collaboration and knowledge sharing among experts. Although currently lacking an H-index, the journal aspires to establish a robust reputation in the medical literature landscape, supporting the ongoing evolution of tailored healthcare solutions. Researchers are encouraged to contribute their findings to enhance the journal’s commitment to excellence in precision medical sciences.

Oncologie is a distinguished academic journal published by WALTER DE GRUYTER GMBH, focusing on the dynamic and vital field of oncology. Established in 1999 and continuously published until 2024, this journal provides a platform for high-quality research and advancements in cancer treatment, prevention, and diagnosis. With an ISSN of 1292-3818 and an E-ISSN of 1765-2839, it is indexed in various databases, contributing to its growing visibility. Although categorized in the Q3 quartile for oncology research as of 2023, Oncologie offers essential insights and fosters scholarly dialogue among researchers, professionals, and students interested in oncology. Its unique contributions aim to bridge the gap between theoretical frameworks and clinical applications, making it a valuable resource for those seeking to advance their knowledge and expertise in cancer research.

World Journal of Gastrointestinal Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a pivotal resource in the evolving fields of gastroenterology and oncology, particularly focused on the intricate relationship between gastrointestinal disorders and cancer. Established in 2014, the journal continues to publish influential research, boasting a commendable Q2 ranking in both the gastroenterology and oncology categories for 2023, which underscores its importance in these critical medical domains. With a diverse range of topics and studies, it serves as an essential platform for researchers, healthcare professionals, and students aiming to stay informed about the latest advancements and innovations in gastrointestinal oncology. Though currently not classified as open access, the journal's rigorous peer-review process ensures the dissemination of high-quality research that significantly contributes to clinical practice and patient care. Its positioning in the Scopus rankings also highlights its competitive standing within the scientific community, fostering discussions that are crucial for advancing both fields. Explore the latest insights and findings to enhance your understanding and contribute to the ongoing dialogue in gastrointestinal health and oncology.

Nature Reviews Clinical Oncology is a premier journal dedicated to the comprehensive exploration and critical evaluation of current advancements in the field of clinical oncology. Published by the esteemed NATURE PORTFOLIO in the United Kingdom, this influential journal boasts an impressive impact factor that reflects its significant role in shaping oncology research. As a Q1 ranked journal in Scopus, it occupies a notable position within the top tier of oncology publications, placing it in the 99th percentile among its peers. With a history of convergence from 2009 to 2024, it presents high-quality content through an open-access model, ensuring accessibility to vital research findings. Researchers, professionals, and students alike will find Nature Reviews Clinical Oncology an invaluable resource for staying abreast of the latest trends, biologic insights, and therapeutic innovations that drive the future of cancer treatment.